Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
Copyright © 2021 Massachusetts Medical Society..
BACKGROUND: At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19). After emergency use of the vaccine was authorized, the protocol was amended to include an open-label phase. Final analyses of efficacy and safety data from the blinded phase of the trial are reported.
METHODS: We enrolled volunteers who were at high risk for Covid-19 or its complications; participants were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo, 28 days apart, at 99 centers across the United States. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The data cutoff date was March 26, 2021.
RESULTS: The trial enrolled 30,415 participants; 15,209 were assigned to receive the mRNA-1273 vaccine, and 15,206 to receive placebo. More than 96% of participants received both injections, 2.3% had evidence of SARS-CoV-2 infection at baseline, and the median follow-up was 5.3 months in the blinded phase. Vaccine efficacy in preventing Covid-19 illness was 93.2% (95% confidence interval [CI], 91.0 to 94.8), with 55 confirmed cases in the mRNA-1273 group (9.6 per 1000 person-years; 95% CI, 7.2 to 12.5) and 744 in the placebo group (136.6 per 1000 person-years; 95% CI, 127.0 to 146.8). The efficacy in preventing severe disease was 98.2% (95% CI, 92.8 to 99.6), with 2 cases in the mRNA-1273 group and 106 in the placebo group, and the efficacy in preventing asymptomatic infection starting 14 days after the second injection was 63.0% (95% CI, 56.6 to 68.5), with 214 cases in the mRNA-1273 group and 498 in the placebo group. Vaccine efficacy was consistent across ethnic and racial groups, age groups, and participants with coexisting conditions. No safety concerns were identified.
CONCLUSIONS: The mRNA-1273 vaccine continued to be efficacious in preventing Covid-19 illness and severe disease at more than 5 months, with an acceptable safety profile, and protection against asymptomatic infection was observed. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:385 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 385(2021), 19 vom: 04. Nov., Seite 1774-1785 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
El Sahly, Hana M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2019-nCoV Vaccine mRNA-1273 |
|---|
| Anmerkungen: |
Date Completed 16.11.2021 Date Revised 23.11.2023 published: Print-Electronic ClinicalTrials.gov: NCT04470427 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2113017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330930834 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330930834 | ||
| 003 | DE-627 | ||
| 005 | 20231225212345.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2113017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1103.xml |
| 035 | |a (DE-627)NLM330930834 | ||
| 035 | |a (NLM)34551225 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a El Sahly, Hana M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.11.2021 | ||
| 500 | |a Date Revised 23.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04470427 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19). After emergency use of the vaccine was authorized, the protocol was amended to include an open-label phase. Final analyses of efficacy and safety data from the blinded phase of the trial are reported | ||
| 520 | |a METHODS: We enrolled volunteers who were at high risk for Covid-19 or its complications; participants were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo, 28 days apart, at 99 centers across the United States. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The data cutoff date was March 26, 2021 | ||
| 520 | |a RESULTS: The trial enrolled 30,415 participants; 15,209 were assigned to receive the mRNA-1273 vaccine, and 15,206 to receive placebo. More than 96% of participants received both injections, 2.3% had evidence of SARS-CoV-2 infection at baseline, and the median follow-up was 5.3 months in the blinded phase. Vaccine efficacy in preventing Covid-19 illness was 93.2% (95% confidence interval [CI], 91.0 to 94.8), with 55 confirmed cases in the mRNA-1273 group (9.6 per 1000 person-years; 95% CI, 7.2 to 12.5) and 744 in the placebo group (136.6 per 1000 person-years; 95% CI, 127.0 to 146.8). The efficacy in preventing severe disease was 98.2% (95% CI, 92.8 to 99.6), with 2 cases in the mRNA-1273 group and 106 in the placebo group, and the efficacy in preventing asymptomatic infection starting 14 days after the second injection was 63.0% (95% CI, 56.6 to 68.5), with 214 cases in the mRNA-1273 group and 498 in the placebo group. Vaccine efficacy was consistent across ethnic and racial groups, age groups, and participants with coexisting conditions. No safety concerns were identified | ||
| 520 | |a CONCLUSIONS: The mRNA-1273 vaccine continued to be efficacious in preventing Covid-19 illness and severe disease at more than 5 months, with an acceptable safety profile, and protection against asymptomatic infection was observed. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.) | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 700 | 1 | |a Baden, Lindsey R |e verfasserin |4 aut | |
| 700 | 1 | |a Essink, Brandon |e verfasserin |4 aut | |
| 700 | 1 | |a Doblecki-Lewis, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Judith M |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Evan J |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Thomas B |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Jesse |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Lisa A |e verfasserin |4 aut | |
| 700 | 1 | |a Fichtenbaum, Carl J |e verfasserin |4 aut | |
| 700 | 1 | |a Zervos, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Rankin, Bruce |e verfasserin |4 aut | |
| 700 | 1 | |a Eder, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Feldman, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Kennelly, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Han-Conrad, Laurie |e verfasserin |4 aut | |
| 700 | 1 | |a Levin, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Neuzil, Kathleen M |e verfasserin |4 aut | |
| 700 | 1 | |a Corey, Lawrence |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Janes, Holly |e verfasserin |4 aut | |
| 700 | 1 | |a Follmann, Dean |e verfasserin |4 aut | |
| 700 | 1 | |a Marovich, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Polakowski, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Mascola, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Ledgerwood, Julie E |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Barney S |e verfasserin |4 aut | |
| 700 | 1 | |a August, Allison |e verfasserin |4 aut | |
| 700 | 1 | |a Clouting, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Weiping |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Leav, Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Manzo, Deb |e verfasserin |4 aut | |
| 700 | 1 | |a Pajon, Rolando |e verfasserin |4 aut | |
| 700 | 1 | |a Schödel, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Tomassini, Joanne E |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Honghong |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Jacqueline |e verfasserin |4 aut | |
| 700 | 0 | |a COVE Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Adams, Atoya |e investigator |4 oth | |
| 700 | 1 | |a Miller, Eric |e investigator |4 oth | |
| 700 | 1 | |a Rankin, Bruce G |e investigator |4 oth | |
| 700 | 1 | |a Hill, John |e investigator |4 oth | |
| 700 | 1 | |a Shinn, Steven |e investigator |4 oth | |
| 700 | 1 | |a Nash, Marshall |e investigator |4 oth | |
| 700 | 1 | |a Green, Sinikka L |e investigator |4 oth | |
| 700 | 1 | |a Jacobsen, Colleen |e investigator |4 oth | |
| 700 | 1 | |a Krishnankutty, Jayasree |e investigator |4 oth | |
| 700 | 1 | |a Phungwayo, Sikhongi |e investigator |4 oth | |
| 700 | 1 | |a Glover, Richard M |c 2nd |e investigator |4 oth | |
| 700 | 1 | |a Slechta, Drs Stacy |e investigator |4 oth | |
| 700 | 1 | |a Holdeman, Troy |e investigator |4 oth | |
| 700 | 1 | |a Hartvickson, Robyn |e investigator |4 oth | |
| 700 | 1 | |a Grant, Amber |e investigator |4 oth | |
| 700 | 1 | |a Poling, Terry L |e investigator |4 oth | |
| 700 | 1 | |a Klein, Terry D |e investigator |4 oth | |
| 700 | 1 | |a Klein, Thomas C |e investigator |4 oth | |
| 700 | 1 | |a Klein, Tracy R |e investigator |4 oth | |
| 700 | 1 | |a Smith, William B |e investigator |4 oth | |
| 700 | 1 | |a Gibson, Richard L |e investigator |4 oth | |
| 700 | 1 | |a Winbigler, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Parker, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Wijewardane, Priyantha N |e investigator |4 oth | |
| 700 | 1 | |a Bravo, Eric |e investigator |4 oth | |
| 700 | 1 | |a Thessing, Jeffrey |e investigator |4 oth | |
| 700 | 1 | |a Maxwell, Michelle |e investigator |4 oth | |
| 700 | 1 | |a Horn, Amanda |e investigator |4 oth | |
| 700 | 1 | |a Sahly, Hana El |e investigator |4 oth | |
| 700 | 1 | |a Whitaker, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Healy, Catherine Mary |e investigator |4 oth | |
| 700 | 1 | |a Akamine, Christine |e investigator |4 oth | |
| 700 | 1 | |a Chu, Laurence |e investigator |4 oth | |
| 700 | 1 | |a Chouteau, R Michelle |e investigator |4 oth | |
| 700 | 1 | |a Cotugno, Michael J |e investigator |4 oth | |
| 700 | 1 | |a Bauer, George H |c Jr |e investigator |4 oth | |
| 700 | 1 | |a Hachigian, Greg |e investigator |4 oth | |
| 700 | 1 | |a Oshita, Masaru |e investigator |4 oth | |
| 700 | 1 | |a Cancilla, Michael |e investigator |4 oth | |
| 700 | 1 | |a Murray, Deborah |e investigator |4 oth | |
| 700 | 1 | |a Kiersey, Kristen |e investigator |4 oth | |
| 700 | 1 | |a Seger, William |e investigator |4 oth | |
| 700 | 1 | |a Antwi, Mohammed |e investigator |4 oth | |
| 700 | 1 | |a Green, Allison |e investigator |4 oth | |
| 700 | 1 | |a Kim, Anthony |e investigator |4 oth | |
| 700 | 1 | |a Baden, Lindsey R |e investigator |4 oth | |
| 700 | 1 | |a Desjardins, Michael |e investigator |4 oth | |
| 700 | 1 | |a Johnson, Jennifer A |e investigator |4 oth | |
| 700 | 1 | |a Sherman, Amy |e investigator |4 oth | |
| 700 | 1 | |a Walsh, Stephen R |e investigator |4 oth | |
| 700 | 1 | |a Borger, Judith |e investigator |4 oth | |
| 700 | 1 | |a Starr, Ryan |e investigator |4 oth | |
| 700 | 1 | |a Syndergaard, Scott |e investigator |4 oth | |
| 700 | 1 | |a Saleem, Nafisa |e investigator |4 oth | |
| 700 | 1 | |a Solis, Joel |e investigator |4 oth | |
| 700 | 1 | |a Medina, Martha Carmen |e investigator |4 oth | |
| 700 | 1 | |a Keating, Westly |e investigator |4 oth | |
| 700 | 1 | |a Garcia, Edgar |e investigator |4 oth | |
| 700 | 1 | |a Bueno, Cynthia |e investigator |4 oth | |
| 700 | 1 | |a Segall, Nathan |e investigator |4 oth | |
| 700 | 1 | |a Finley, Jon |e investigator |4 oth | |
| 700 | 1 | |a Stull, Mildred |e investigator |4 oth | |
| 700 | 1 | |a Denham, Douglas Scott |e investigator |4 oth | |
| 700 | 1 | |a Weiss, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Avworo, Ayoade |e investigator |4 oth | |
| 700 | 1 | |a Hedges, Parke |e investigator |4 oth | |
| 700 | 1 | |a Becher Strout, Cynthia |e investigator |4 oth | |
| 700 | 1 | |a Santiago, Rica |e investigator |4 oth | |
| 700 | 1 | |a Davis, Yvonne |e investigator |4 oth | |
| 700 | 1 | |a Howenstine, Patty |e investigator |4 oth | |
| 700 | 1 | |a Bondell, Alison |e investigator |4 oth | |
| 700 | 1 | |a Marks, Kristin |e investigator |4 oth | |
| 700 | 1 | |a Ellsworth, Grant |e investigator |4 oth | |
| 700 | 1 | |a Wang, Tina |e investigator |4 oth | |
| 700 | 1 | |a Wilkin, Timothy |e investigator |4 oth | |
| 700 | 1 | |a Vogler, Mary |e investigator |4 oth | |
| 700 | 1 | |a Johnston, Carrie |e investigator |4 oth | |
| 700 | 1 | |a Andrasik, Michele P |e investigator |4 oth | |
| 700 | 1 | |a Andriesen, Jessica G |e investigator |4 oth | |
| 700 | 1 | |a Broder, Gail |e investigator |4 oth | |
| 700 | 1 | |a Corey, Lawrence |e investigator |4 oth | |
| 700 | 1 | |a Eaton, Niles |e investigator |4 oth | |
| 700 | 1 | |a Neuzil, Kathleen M |e investigator |4 oth | |
| 700 | 1 | |a Gelderblom, Huub G |e investigator |4 oth | |
| 700 | 1 | |a Kublin, James G |e investigator |4 oth | |
| 700 | 1 | |a McClennen, Rachael |e investigator |4 oth | |
| 700 | 1 | |a Michael, Nelson |e investigator |4 oth | |
| 700 | 1 | |a Robb, Merlin |e investigator |4 oth | |
| 700 | 1 | |a Sopher, Carrie |e investigator |4 oth | |
| 700 | 1 | |a Miller, Vicki E |e investigator |4 oth | |
| 700 | 1 | |a Santiago, Fredric |e investigator |4 oth | |
| 700 | 1 | |a Gomez, Blanca |e investigator |4 oth | |
| 700 | 1 | |a Valika, Insiya |e investigator |4 oth | |
| 700 | 1 | |a Starr, Amy |e investigator |4 oth | |
| 700 | 1 | |a Kelley, Colleen |e investigator |4 oth | |
| 700 | 1 | |a Cantos, Valeria D |e investigator |4 oth | |
| 700 | 1 | |a Kandiah, Sheetal |e investigator |4 oth | |
| 700 | 1 | |a Del Rio, Carlos A |e investigator |4 oth | |
| 700 | 1 | |a Rouphael, Nadine |e investigator |4 oth | |
| 700 | 1 | |a Rebolledo, Paulina |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 385(2021), 19 vom: 04. Nov., Seite 1774-1785 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:385 |g year:2021 |g number:19 |g day:04 |g month:11 |g pages:1774-1785 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2113017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 385 |j 2021 |e 19 |b 04 |c 11 |h 1774-1785 | ||